Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR CLEAN-MED trial
2017-001466-21Phase 3Active
- Sponsor
- Erasmus MC
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of heparin and aspirin in ischemic stroke (4 arms), sponsored by Erasmus MC. Primary endpoint: Modified Rankin Scale at 90 days. Started Aug 2017; status: active.
02
Drugs
heparinaspirin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2017-001466-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001466-21.